Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664986 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL10607843 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL30471514 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL9980671 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL7057277 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL7439787 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL30471384 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL6891888 | 1.00 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL148100 | 0.92 | CA1 (0.52) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL148099 | 0.92 | CA1 (0.52) | KMT2ACTSKCTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259846-B2 | Bouvardin derivatives and therapeutic uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3345624-A1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | The Regents Of The University Of Colorado (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2817004-B1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | UNIV COLORADO REGENTS (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170218025-A1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | SUVICA, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9452215-B2 | Bourvadin derivatives and therapeutic uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150238562-A1 | BOURVADIN DERIVATIVES AND THERAPEUTIC USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2015-08-27 | — | — | US | disclosed |
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259846-B2 | Bouvardin derivatives and therapeutic uses thereof | EIF4E, EIF4EBP1, RPL30 | KMT2A 2637/4885CTSK 2933/4885CTSS 3663/4885 |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | KMT2A 3242/4885CTSK 3343/4885CTSS 4178/4885 |
| US-20170218025-A1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | EIF4E, EIF4EBP1, RPL30 | KMT2A 2637/4885CTSK 2933/4885CTSS 3663/4885 |
| US-20150238562-A1 | BOURVADIN DERIVATIVES AND THERAPEUTIC USES THEREOF | RPL27, EIF4E, RPL30 | KMT2A 2928/4885CTSK 2926/4885CTSS 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.